Sequential versus concurrent neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a randomized, controlled, open-label, phase 2 trial (HCHTOG1906) - Takeaways - MDSpire

Sequential versus concurrent neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a randomized, controlled, open-label, phase 2 trial (HCHTOG1906)

  • By

  • Yan Zheng

  • Jiwei Wu

  • Lingdi Zhao

  • Yaxing Shen

  • Guanghui Liang

  • Keting Li

  • Quanli Gao

  • Wenqun Xing

  • May 7, 2026

Share

  • 1

    The study involved 70 patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC) from July 2019 to June 2023.

  • 2

    The primary endpoint was pathological complete remission (pCR), with an overall rate of 22.2% and no significant difference between sequential and concurrent groups.

  • 3

    The concurrent group experienced significantly higher rates of nausea and diarrhea, with 14.2% of participants reporting grade 3–5 treatment-related adverse events.

  • 4

    Six treatment-related fatalities occurred, with five in the concurrent group and one in the sequential group, indicating higher risks associated with concurrent therapy.

  • 5

    No significant differences in overall survival or disease-free survival were found between the sequential and concurrent immunochemotherapy approaches.

Original Source(s)

Sequential versus concurrent neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a randomized, controlled, open-label, phase 2 trial (HCHTOG1906)

  • by Yan Zheng, Jiwei Wu, Lingdi Zhao, Yaxing Shen, Guanghui Liang, Keting Li, Quanli Gao, Wenqun Xing

  • May 7, 2026

Related Content

One Pathway for Esophageal Cancer?

Molecular profiling reveals precursor signals in BE-negative esophageal cancer

  • May 7, 2026

  • 2 min
Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study

In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alon...

‘Promising’ Signal Only: ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use

Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer...